中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (8): 576-579.doi: 10.12144/zgmfskin202308576

• 临床研究 • 上一篇    下一篇

度普利尤单抗成功治疗嗜酸性粒细胞增多综合征一例

丁高中1,李姗姗2,孙澜1,魏云1   

  1. 1南京医科大学附属苏州医院 苏州市立医院东区皮肤科，江苏苏州，215001；2苏州大学附属传染病医院，苏州市第五人民医院皮肤科，江苏苏州，215001
  • 出版日期:2023-08-15 发布日期:2023-07-19

A case of hypereosinophilic syndrome successfully treated with dupilumab

DING Gaozhong1, LI Shanshan2, SUN Lan1, WEI Yun1   

  1. 1 Department of Dermatology, the Affiliated Suzhou Hospital of Nanjing Medical University，East District of Suzhou Municipal Hospital, Suzhou 215001, China; 2 Department of Dermatology, the Fifth People's Hospital of Suzhou, Suzhou 215001, China
  • Online:2023-08-15 Published:2023-07-19

PDF (PC)

278

摘要： 目前国外有度普利尤单抗治疗嗜酸性粒细胞增多综合征报道，国内尚无相关报道。本文首报度普利尤单抗治疗嗜酸性粒细胞增多综合征1例，患者首次注射剂量600 mg，1周后予以300 mg皮下注射，之后每2周皮下注射300 mg，患者治疗3周后，瘙痒明显缓解，7周后皮损基本消退。首剂治疗后第3天出现下肢丹毒，经抗感染治疗好转。

关键词: 嗜酸性粒细胞增多综合征, 度普利尤单抗, 丹毒

Abstract: Treatment of hypereosinophilic syndrome with dupriulizumab has been reported abroad, but not in China. Herein, we report a case of dupriulizumab in the treatment of hypereosinophilic syndrome successfully. The patient received subcutaneous injection of dupilumab at an initial dose of 600 mg, 300 mg after 1 week, then once every 2 weeks with a dose of 300 mg. After 3 weeks of treatment, the pruritus was significantly relieved, and the skin lesions basically subsided after 7 weeks. Erysipelas appeared on the 3rd day after the first dose of treatment, which was improved by anti-infection.

Key words: hypereosinophilic syndrome, dupilumab, erysipelas